Treatment of influenza A (H1N1) virus infection with ribavirin aerosol.

AUTOR(ES)

Wilson, S Z

RESUMO

In a randomized, controlled study of ribavirin aerosol treatment of influenza A(H1N1) virus infection among college students, treated patients had a significantly shorter duration of fever than control patients. There was a trend of more rapid recovery in treated patients. Virus shedding was similar in treated and control patients, declining gradually from a 50% tissue culture infective dose of 3.5 log10 per ml at admission to 1.8 log10 per ml at 53 h after admission. There was no local or systemic intolerance and no hematological or biochemical abnormalities associated with ribavirin treatment.

Documentos Relacionados

• Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol.
• Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.
• Ribavirin small-particle-aerosol treatment of influenza B virus infection.
• Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo.
• Cell-mediated immune response of human lymphocytes to influenza A/USSR (H1N1) virus infection.